Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2024. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. 

Third quarter financial results 2024 (1 July - 30 September):

• Net Revenue was KDKK 3.356
• Operating result was KDKK -925
• Net result was KDKK -1.132
• Cash at bank end of the period was KDKK 5.944
• Earnings per share* was KDKK -0,06
• Solidity** was 77%

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 September 2024 amounted to 17.425.094 shares, the average number of shares during the third quarter was 17.425.094 
**Solidity: Total equity divided by total capital and liability

Comment from CEO, Jes Trygved:
The commercialization and partnership agreement with Proveca Ltd, was a major effort and milestone for the company. A process that started last year, identifying the right partner for the registration and commercialization of CT001 for Europe and selected markets in rest of the world, has materialized and we are very pleased with the outcome. We are also pleased to have seen very good progress with the Paediatric Safety Study 0202, which has now reached the 50% enrolment mark. We are still spending significant time and effort on the manufacturing and launch of CT001 for the US market, this is another major milestone, and we hope soon to have a final launch date. Thanks for a great effort by the team !

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.